FMFrances B. Maguire

Frances B. Maguire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frances B. Maguire has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Theresa H. M. Keegan

    Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis Comprehensive Cancer Center, Sacramento, CA

    9 shared publications
  • Arti Parikh-Patel

    California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento

    7 shared publications
  • Renata Abrahão

    Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis Comprehensive Cancer Center, Sacramento, CA

    5 shared publications
  • Theresa H. M. Keegan

    UC Davis Health University of California Davis Comprehensive Cancer Center Sacramento California USA

    5 shared publications
  • Arti Parikh-Patel

    California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

    4 shared publications
  • Brenda M. Hofer

    UC Davis Health University of California Davis Comprehensive Cancer Center Sacramento California USA

    3 shared publications

Latest Publications

  • Quality of Cancer Care in California After Full Implementation of the Affordable Care Act: Findings From a Population-Based Study

    by Arti Parikh-Patel, Nuen Tsang Yang, Frances B. Maguire, Brenda M. Hofer, Theodore Wun, Theresa H.M. Keegan, Shehnaz K. Hussain


  • Open Access

    Table S1 from Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California

    by Julianne J.P. Cooley, Frances B. Maguire, Cyllene R. Morris, Arti Parikh-Patel, Renata Abrahão, Hui A. Chen, Theresa H.M. Keegan

    Supplementary Table S1. Association between sociodemographic and clinical characteristics with late-stage (II-IV, Unknown*) cervical cancer diagnosis for patients ≥65 years, 2009-2018 (N=2,420)

  • Open Access

    Data from Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California

    by Julianne J.P. Cooley, Frances B. Maguire, Cyllene R. Morris, Arti Parikh-Patel, Renata Abrahão, Hui A. Chen, Theresa H.M. Keegan

    Background:Through adequate screening and follow-up, cervical cancer can be prevented or detected at early-stage (stage I), which is related to excellent survival. Current guidelines recommend discontinuing screening for women ≥65 years with history of normal Pap and/or HPV tests, potentially leaving this age group vulnerable. This study examined late-stage disease in a population-based cohort.Methods:Using California Cancer Registry data, we identified 12,442 patients ages ≥21 years with a first primary cervical cancer diagnosed during 2009–2018. Proportions of late-stage disease (stages II–IV) and early- and late-stage 5-year relative survival are presented by the age group. Among patients ages ≥65 years, multivariable logistic regression estimated associations of sociodemographic and clinical characteristics with late-stage cervical cancer.Results:Nearly one fifth of patients (n = 2,171, 17.4%) were ≥65 years. More women ages ≥65 years (71%) presented with late-stage disease than younger women (48% in patients ages <65). Late-stage 5-year relative survival was lower for women ≥65 years (23.2%–36.8%) compared with patients <65 (41.5%–51.5%). Characteristics associated with late-stage cervical cancer in women ≥65 years included older age [odds ratio (OR), 1.02; 95% confidence interval (CI), 1.01–1.04; each year], non-adenocarcinoma histologic subtypes, and comorbidities (OR, 1.59; 95% CI, 1.21–2.08).Conclusions:There remains a significant burden of advanced cervical cancer in women ≥65.Impact:Efforts should be made to better understand how the current screening paradigm is failing women of 65 years and older. Future work should focus on determining past screening history, lapses in follow-up care, and non-invasive testing approaches.

  • Open Access

    Cancer Incidence and Trends in Persistent Poverty Areas of California by Race/Ethnicity and Sex

    by Ani S. Movsisyan Vernon, Frances B. Maguire, Ayman T. Ullah, Brenda M. Hofer, Arti Parikh‐Patel, Ted Wun, Shehnaz K. Hussain, Theresa H. M. Keegan

    Background: Although previous studies have observed the relationship between living in persistent poverty areas (PPAs) and adverse cancer outcomes, the relationship between residing in PPAs and disparities in cancer incidence rates and temporal trends by race/ethnicity and sex in California is unknown. Methods: We used California Cancer Registry data to identify patients diagnosed with 16 common cancers between 2006 and 2020. We calculated age‐adjusted incidence rates (IRs), incidence rate ratios (IRRs), and average annual percent changes (AAPCs) to compare incidence and temporal trends in PPAs and non‐PPAs in California by race/ethnicity and sex. PPA was defined as areas with a poverty rate of 20% or more for approximately 30 continuous years. Results: Male patients in PPAs had significantly higher IRRs of colorectal, liver, lung, and stomach cancers, and female patients had higher cervical, kidney, liver, and stomach cancers. Across all racial/ethnic groups, cervical and liver cancer IRRs were significantly higher, and IRRs for female breast cancer were lower in PPAs. The incidence of several cancers significantly decreased over time only in non‐PPAs. Colorectal cancer and non‐Hodgkin lymphoma among Hispanic residents significantly increased in PPAs (AAPC = 0.4, 1.2) and colorectal cancer decreased only in non‐PPAs (AAPC = −1.4). Thyroid cancer among non‐Hispanic Black residents increased only in PPAs (AAPC = 4.7). Conclusion: Our findings highlight race/ethnicity and sex disparities in cancer incidence and temporal trends for PPA residents. Further research is needed to understand the specific etiological factors underlying these disparities, and to support the development of public health policies and initiatives to decrease the cancer burden in California.

  • The effect of body mass index on breast cancer stage and breast cancer specific survival

    by A. Bellini, T. H. M. Keegan, Q. Li, A. Jacinto, F. B. Maguire, V. Lyo, C. A. M. Sauder

    Purpose Underweight women and those with obesity, defined as having a body mass index (BMI) ≥ 30 kg/m2, diagnosed with breast cancer (BC) are known to have worse prognosis. Whether BMI impacts BC stage at diagnosis and BC specific survival (BCSS) is not understood. We aim to better understand the relationship between BMI with stage at BC diagnosis and BCSS. Methods Women age ≥ 15 years old diagnosed with BC between 2014 and 2019 were identified from the California Cancer Registry. BMI at diagnosis was classified as underweight (< 18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), obesity class 1–2 (30–39.9 kg/m2), and obesity class 3 (≥ 40 kg/m2). BC late stage of diagnosis was defined as American Joint Committee on Cancer stage 3 and 4. Multivariate logistic regression was performed to compare sociodemographic and clinical factors associated with late stage. Multivariable cox proportional hazards regression models assessed association of BMI and BCSS. Results Of 159,248 patients: 2.2% were underweight, 34.6% normal weight, 30.5% overweight, 26.7% obesity class 1–2, and 6.0% obesity class 3. Compared to normal weight, patients who were underweight [Hazard Ratio (HR) 1.54, 95% Confidence Interval (CI) 1.51–1.57], obesity class 1–2 [HR 1.06, 1.05–1.07], and obesity class 3 [HR 1.14, 1.12–1.16] were more likely to be diagnosed with late-stage BC. In models stratified by age, patients ≥ 40 years who were underweight had worse BCSS, while patients ≥ 51 years with obesity class 1–2 had better BCSS. Conclusion Patients with obesity class 1–2 were more likely to be diagnosed with a later stage, but had improved BCSS, supporting an “obesity paradox” in BC and suggesting that other measures are needed to better assess body composition, adipose distribution, and metabolic health of patients. Patients who were underweight had worse survival, suggesting this high-risk group may benefit from being assessed and treated for possible sarcopenia and malnourishment.


  • Receipt of Guideline-Concordant Care Is Associated With Improved Survival in Patients With Osteosarcoma in California: A Population-Based Analysis

    by Renata Abrahão, Theresa H.M. Keegan, Frances B. Maguire, Qian Li, Marcio H. Malogolowkin, Samantha Wong, Steven W. Thorpe, Janai R. Carr-Asher, Amanda M. Midboe, R. Lor Randall, et al.

    PURPOSE: To examine the relationship between guideline-concordant care (GCC) on the basis of national clinical practice guidelines and survival in children (0-14 years), adolescents and young adults (AYAs, 15-39 years), and adults (40 years and older) with osteosarcoma, and to identify sociodemographic and clinical factors associated with receipt of GCC and survival. METHODS: We used data from the California Cancer Registry (CCR) on patients diagnosed with osteosarcoma during 2004-2019, with detailed treatment information extracted from the CCR text fields, including chemotherapy regimens. Multivariable logistic and Cox proportional hazard regression were used for statistical analyses. RESULTS: Of 1,716 patients, only 47% received GCC, with variation by age at diagnosis: 67% of children, 43% of AYAs, and 30% of adults. In multivariable models, patients who received part or all care ( v none) at specialized cancer centers were more likely to receive GCC. AYAs and adults were less likely to receive GCC than children (odds ratio [OR], 0.38 [95% CI, 0.30 to 0.50] and OR, 0.40 [95% CI, 0.28 to 0.56], respectively). In a model excluding adults, patients treated by pediatric ( v medical) oncologists were more likely to receive GCC (OR, 3.44 [95% CI, 2.40 to 4.94]). Patients with metastatic osteosarcoma at diagnosis who did not receive GCC had a greater hazard of death (hazard ratio [HR], 2.02 [95% CI, 1.55 to 2.63]) but no statistical differences were found in those diagnosed at earlier stages (HR, 1.15 [95% CI, 0.92 to 1.43]). CONCLUSION: GCC was associated with improved survival in patients with metastatic osteosarcoma in California. However, we found disparities in the delivery of GCC, highlighting the need for target interventions to improve delivery of GCC in this patient population.


  • Disparities in the Occurrence of Long-Term Effects of Bone Marrow Suppression after Treatment in Adolescent Young Adult Breast Cancer Survivors

    by A. Bellini, T. H. M. Keegan, Q. Li, F. B. Maguire, V. Lyo, Candice Sauder

    Many adolescent and young adult (AYA) patients with breast cancer (BC) receive adjuvant therapy as initial treatment, with long-term bone marrow suppressio


  • Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California

    by Julianne J.P. Cooley, Frances B. Maguire, Cyllene R. Morris, Arti Parikh-Patel, Renata Abrahão, Hui A. Chen, Theresa H.M. Keegan

    Background: Through adequate screening and follow-up, cervical cancer can be prevented or detected at early-stage (stage I), which is related to excellent survival. Current guidelines recommend discontinuing screening for women ≥65 years with history of normal Pap and/or HPV tests, potentially leaving this age group vulnerable. This study examined late-stage disease in a population-based cohort. Methods: Using California Cancer Registry data, we identified 12,442 patients ages ≥21 years with a first primary cervical cancer diagnosed during 2009–2018. Proportions of late-stage disease (stages II–IV) and early- and late-stage 5-year relative survival are presented by the age group. Among patients ages ≥65 years, multivariable logistic regression estimated associations of sociodemographic and clinical characteristics with late-stage cervical cancer. Results: Nearly one fifth of patients (n = 2,171, 17.4%) were ≥65 years. More women ages ≥65 years (71%) presented with late-stage disease than younger women (48% in patients ages <65). Late-stage 5-year relative survival was lower for women ≥65 years (23.2%–36.8%) compared with patients <65 (41.5%–51.5%). Characteristics associated with late-stage cervical cancer in women ≥65 years included older age [odds ratio (OR), 1.02; 95% confidence interval (CI), 1.01–1.04; each year], non-adenocarcinoma histologic subtypes, and comorbidities (OR, 1.59; 95% CI, 1.21–2.08). Conclusions: There remains a significant burden of advanced cervical cancer in women ≥65. Impact: Efforts should be made to better understand how the current screening paradigm is failing women of 65 years and older. Future work should focus on determining past screening history, lapses in follow-up care, and non-invasive testing approaches.


  • Open Access

    Evaluation of Cancer Deaths Attributable to Tobacco in California, 2014-2019

    by Frances B. Maguire, Ani S. Movsisyan, Cyllene R. Morris, Arti Parikh-Patel, Theresa H. M. Keegan, Elisa K. Tong

    Smoking is associated with 12 types of cancer (oral cavity and pharynx, larynx, esophagus, lung, liver, stomach, pancreas, kidney, urinary bladder, colon and rectum, uterine cervix, and acute myeloid leukemia [AML]) and remains the largest preventable factor associated with death from cancer and other diseases.1 The California Tobacco Control Program, established in 1989, has been associated with substantial decreases in cigarette consumption, lung cancer incidence, and heart disease mortality in California through supporting state and community interventions for policy, system, and environmental change on tobacco.2-4 California’s cigarette consumption has decreased faster compared with other states, and it now has the second lowest smoking rate in the US.5 From 1979 to 2005, California’s smoking-attributable cancer mortality (SACM) decreased by approximately 26% compared with 9% for the rest of the US, and from 1986 to 2013, its annual lung cancer mortality was 28% lower than in the rest of the US.6,7 Despite these successes, California still has more than 3 million people who smoke.8


  • Open Access

    Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: A population‐based study

    by Justine M. Kahn, Frances B. Maguire, Qian Li, Renata Abrahão, Jamie E. Flerlage, Elysia Alvarez, Theresa H. M. Keegan

    Background: Hodgkin lymphoma (HL) is a treatable tumor affecting children, adolescents and young adults (AYAs; 15‐39 years old). Population‐based studies report worse survival for non‐White children and AYAs but have limited data on individual therapeutic exposures. This study examined overall and HL‐specific survival in a population‐based cohort of patients while adjusting for sociodemographic factors and treatment.Methods: Data for 4807 patients younger than 40 years with HL (2007‐2017) were obtained from the California Cancer Registry. Individual treatment information was extracted from text fields; chemotherapy regimens were defined by standard approaches for pediatric and adult HL. Multivariable Cox models examined the influence of patient and treatment factors on survival.Results: At a median follow‐up of 4.4 years, 95% of the patients were alive. Chemotherapy differed by age, with 70% of 22‐ to 39‐year‐olds and 41% of P < .001). In multivariable models, older patients (22‐39 vs < 21 y; hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.11‐2.10), Black (vs White patients); HR, 1.90; 95% CI, 1.25‐2.88), and Hispanic patients (HR, 1.45; 95% CI, 1.06‐1.99) experienced worse survival; among those < 21 y, Black race was associated with a 3.3‐fold increased risk of death (HR, 3.26; 95% CI, 1.43‐7.42).Conclusions: In children and AYAs with HL, older age and non‐White race/ethnicity predicted worse survival after adjustments for treatment data. Further work is needed to identify the biological and nonbiological factors driving disparities in these at‐risk populations.